Resveratrol as a Therapeutic Agent for Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is the most common cause of dementia, but there is no effective therapy till now. The pathogenic mechanisms of AD are considerably complex, including A β accumulation, tau protein phosphorylation, oxidative stress, and inflammation. Exactly, resveratrol, a polyphenol in red wine and many plants, is indicated to show the neuroprotective effect on mechanisms mostly above. Recent years, there are numerous researches about resveratrol acting on AD in many models, both in vitro and in vivo. However, the effects of resveratrol are limited by its pool bioavailability; therefore researchers have been trying a variety of methods to improve the efficiency. This review summarizes the recent studies in cell cultures and animal models, mainly discusses the molecular mechanisms of the neuroprotective effects of resveratrol, and thus investigates the therapeutic potential in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., et al. (2006) · Cell · doi:10.1016/j.cell.2006.11.013 · Cited by 4,057 · cited 2×
“…mitochondria during oxidative stress, mainly including inducing nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) and these productions may damage the mitochondrial and cellular proteins and nucleic acids, causing lipid peroxidation and resulting in the loss of membrane integrity [15].”
BackgroundKim, D., Nguyen, M. D., Dobbin, M. M., Fischer, A., Sananbenesi, F., Rodgers, J. T., Delalle, I., Baur, J. A., Sui, G., Armour, S. M., et al. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601758 · Cited by 1,074 · cited 2×
“That is to say resveratrol provides neuroprotection and prevents cognitive decline in animal models [40].”
BackgroundBioavailability of resveratrol
Walle, T. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05842.x · Cited by 1,051 · cited 3×
“Studies have shown that the oral absorption of resveratrol appeared to be at least 75%; however the bioavailability was poor on account of the rapid and extensive metabolism [69].”
BackgroundNeuropathology of Alzheimer's Disease
Perl, D. P. (2010) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20157 · Cited by 825
Inflammatory processes in Alzheimer's disease
Heneka, M. T., & O'Banion, M. K. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.11.017 · Cited by 782
Resveratrol stimulates AMP kinase activity in neurons
Dasgupta, B., & Milbrandt, J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610068104 · Cited by 723 · cited 1×
“To extend their in vitro results, Dasgupta and Milbrandt conducted an experiment and found that intraperitoneal injection of resveratrol acutely activated AMP-activated kinase (AMPK) in the brain, probably due to the phosphorylation and inhibition of acetyl-CoA carboxylase (ACC) [35].”
BackgroundAlzheimer's disease: The amyloid cascade hypothesis: An update and reappraisal
Hardy, J. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-9s317 · Cited by 475 · cited 1×
“In 1992, the amyloid hypothesis postulated that Aβ deposits were the elementary cause of AD and since then the hypothesis had been gradually acknowledged [12].”
BackgroundResveratrol is not a direct activator of SIRT1 enzyme activity
Beher, D., Wu, J., Cumine, S., Kim, K. W., Lu, S., Atangan, L., & Wang, M. (2009) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2009.00901.x · Cited by 426 · cited 1×
“It is found that resveratrol possesses the ability to activate SIRT1, although there is a viewpoint that resveratrol is not a direct activator [57].”
Background
Cited by
The Potential of Plant Phenolics in Prevention and Therapy of Skin Disorders
Działo, M., Mierziak, J., Korzun, U., Preisner, M., Szopa, J., & Kulma, A. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17020160 · Cited by 680
Savelieff, M. G., Nam, G., Kang, J., Lee, H. J., Lee, M., & Lim, M. H. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00138 · Cited by 581
Neuroprotective Mechanisms of Resveratrol in Alzheimer’s Disease: Role of SIRT1
Gomes, B. A. Q., Silva, J. P. B., Romeiro, C. F. R., dos Santos, S. M., Rodrigues, C. A., Gonçalves, P. R., Sakai, J. T., Mendes, P. F. S., Varela, E. L. P., & Monteiro, M. C. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/8152373 · Cited by 403
Resveratrol: A miraculous natural compound for diseases treatment
Koushki, M., Amiri‐Dashatan, N., Ahmadi, N., Abbaszadeh, H., & Rezaei‐Tavirani, M. (2018) · Food Science & Nutrition · doi:10.1002/fsn3.855 · Cited by 316
Buckwheat as a Functional Food and Its Effects on Health
Giménez-Bastida, J. A., & Zieliński, H. (2015) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5b02498 · Cited by 306
Metadata
- Authors
- Ma, T., Tan, M.-S., Yu, J.-T., & Tan, L.
- Venue
- BioMed Research International
- Publisher
- Wiley
- Published
- 2014
- Volume
- 2014
- Pages
- 1-13
- ISSN
- 1110-7243 (ISSN-L)
- 2314-6133
- 2314-6141
- OpenAlex
- W2119657643
- Cited by
- 140
- References
- 13
- FWCI
- 6.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Resveratrol as a Therapeutic Agent for Alzheimer’s Disease. https://app.cochat.ai/papers/10.1155/2014/350516
- The paper
- Ma, T., Tan, M.-S., Yu, J.-T., & Tan, L. (2014). Resveratrol as a Therapeutic Agent for Alzheimer’s Disease. BioMed Research International. https://doi.org/10.1155/2014/350516
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.